Sumitomo Pharma Co., Ltd.
SMDPY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $399 | $315 | $556 | $560 |
| % Growth | 26.8% | -43.4% | -0.8% | – |
| Cost of Goods Sold | $153 | $127 | $179 | $157 |
| Gross Profit | $245 | $188 | $377 | $403 |
| % Margin | 61.5% | 59.8% | 67.8% | 71.9% |
| R&D Expenses | $50 | $113 | $132 | $95 |
| G&A Expenses | $181 | $430 | $279 | $180 |
| SG&A Expenses | $181 | $430 | $339 | $217 |
| Sales & Mktg Exp. | $0 | $0 | $60 | $38 |
| Other Operating Expenses | -$14 | $0 | -$17 | $30 |
| Operating Expenses | $217 | $542 | $454 | $343 |
| Operating Income | $29 | -$354 | -$77 | $60 |
| % Margin | 7.2% | -112.6% | -13.9% | 10.8% |
| Other Income/Exp. Net | -$11 | $32 | $29 | $23 |
| Pre-Tax Income | $18 | -$323 | -$48 | $83 |
| Tax Expense | -$6 | -$8 | $49 | $42 |
| Net Income | $24 | -$315 | -$75 | $56 |
| % Margin | 5.9% | -100.1% | -13.4% | 10.1% |
| EPS | 59.49 | -792.79 | -187.55 | 141.99 |
| % Growth | 107.5% | -322.7% | -232.1% | – |
| EPS Diluted | 59.49 | -792.79 | -187.55 | 141.99 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $36 | $32 | $26 |
| Interest Expense | $14 | $4 | $3 | $3 |
| Depreciation & Amortization | $26 | $38 | $41 | $38 |
| EBITDA | $57 | -$281 | -$3 | $124 |
| % Margin | 14.2% | -89.4% | -0.6% | 22.2% |